Deepa Desai
Plus aucun poste en cours
Provenance du réseau au premier degré de Deepa Desai
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Holding Company | Biotechnology | 28 | |
Warner Chilcott Co., Inc.
 Warner Chilcott Co., Inc. Pharmaceuticals: MajorHealth Technology Warner Chilcott Co., Inc. develops, manufactures and markets branded prescription pharmaceutical products. The company is located in Rockaway, NJ
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Deepa Desai via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CONCERT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Clinical Ink, Inc.
 Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Internet Software/Services | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Founder Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Director/Board Member | |
| INNOVIVA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| YPSOMED HOLDING AG | Medical Specialties | Director/Board Member | |
| The University of Chicago | College/University | Doctorate Degree Undergraduate Degree | |
| Copenhagen Business School | College/University | Graduate Degree | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
| SCIBASE HOLDING AB (PUBL) | Medical Specialties | Chairman | |
BioMedInvest AG I
 BioMedInvest AG I Investment ManagersFinance BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million. | Investment Managers | Corporate Officer/Principal | |
Biotech Ventures GP Ltd.
 Biotech Ventures GP Ltd. Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The company is based in St. Peter Port, UK. | Financial Conglomerates | Corporate Officer/Principal | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Darden School Foundation | Director/Board Member | ||
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | President Corporate Officer/Principal | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Novo Nordisk North America, Inc. | Corporate Officer/Principal | ||
| All India Institute of Medical Sciences | College/University | Doctorate Degree | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
| Weill Cornell Medical College | College/University | Director/Board Member Corporate Officer/Principal | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| Liseberg AB | Corporate Officer/Principal | ||
| University of Virginia Darden School of Business | College/University | Director/Board Member | |
| The Leonard N Stern School of Business | College/University | Masters Business Admin Masters Business Admin | |
| BB Biotech Ventures | Chief Executive Officer | ||
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| ALTABA | Investment Trusts/Mutual Funds | Director/Board Member | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor | |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Miscellaneous Commercial Services | Director/Board Member | |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chairman Director/Board Member | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 30 |
| Suisse | 7 |
| Danemark | 6 |
| Royaume-Uni | 5 |
| Suède | 3 |
Sectorielle
| Health Technology | 27 |
| Consumer Services | 8 |
| Finance | 6 |
| Commercial Services | 4 |
| Technology Services | 3 |
Opérationnelle
| Director/Board Member | 151 |
| Corporate Officer/Principal | 70 |
| Independent Dir/Board Member | 41 |
| Chairman | 26 |
| Undergraduate Degree | 23 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| Jean-Pierre Garnier | 28 |
| Anthony Adam Rosenberg | 23 |
| Martin C. Münchbach | 20 |
| Catherine Friedman | 20 |
| Debasish Francois Roychowdhury | 18 |
| Elizabeth Stoner | 18 |
| Morana Jovan-Embiricos | 14 |
| Robert E. Ward | 13 |
| Jesper Høiland | 13 |
| Kate Hermans | 12 |
| Alice Lin Pomponio | 11 |
| Jose Carmona | 11 |
| Brian Harvey | 11 |
| Alison O'Neill | 10 |
- Bourse
- Insiders
- Deepa Desai
- Connexions Sociétés
